APA (7th ed.) Citation

Vargas-Hernández, A., Mace, E. M., Zimmerman, O., Zerbe, C. S., Freeman, A. F., Rosenzweig, S., . . . Forbes, L. R. (2018). Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. Journal of allergy and clinical immunology, 141(6), 2142-2155.e5. https://doi.org/10.1016/j.jaci.2017.08.040

Chicago Style (17th ed.) Citation

Vargas-Hernández, Alexander, et al. "Ruxolitinib Partially Reverses Functional Natural Killer Cell Deficiency in Patients with Signal Transducer and Activator of Transcription 1 (STAT1) Gain-of-function Mutations." Journal of Allergy and Clinical Immunology 141, no. 6 (2018): 2142-2155.e5. https://doi.org/10.1016/j.jaci.2017.08.040.

MLA (9th ed.) Citation

Vargas-Hernández, Alexander, et al. "Ruxolitinib Partially Reverses Functional Natural Killer Cell Deficiency in Patients with Signal Transducer and Activator of Transcription 1 (STAT1) Gain-of-function Mutations." Journal of Allergy and Clinical Immunology, vol. 141, no. 6, 2018, pp. 2142-2155.e5, https://doi.org/10.1016/j.jaci.2017.08.040.